Sponsor content
7 result(s) found, displaying 1 to 7
-
Australian public assessment report (AusPar)Rystiggo has been approved as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Bimzelx bimekizumab 320 mg/2 mL solution for injection auto-injector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Bimzelx bimekizumab 320 mg/2 mL solution for injection safety syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYSTIGGO rozanolixizumab 140 mg/mL solution for injection for infusion vial.
-
Cancellation by sponsorRequested by UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
-
Prescription medicine registrationActive ingredients: bimekizumab.
-
Prescription medicine registrationActive ingredients: rozanolixizumab.